Alternatively, there may be specific epigenetic markings which correspond to NFATC2 transcription in AML specifically, and these should be profiled more extensively, to further identify leukaemogenic epigenetic rewiring which may represent points of therapeutic vulnerability. This evidence concerns the gene NFATC2 and acute myeloid leukemia.